French biotech stock soars 40% after new data on experimental medicine

French biotech company Abivax delivered positive clinical trial results today, sending its stock up forty percent. The experimental bowel-disease treatment, obefazimod, showed promising performance in the latest round of testing, according to CNBC. The data advances the drug toward potential regulatory approval.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton